RespireRx Pharmaceuticals Inc., a Glen Rock-based medicine developer, announced on Wednesday it has named Timothy Jones to CEO and president.
Jones, who signed a three-year contract for the role, has been a member of the company’s board since January 28.
Dr. Arnold Lippa, who has been serving as interim CEO and president, will step down from the role but continue as executive chairman and chief scientific officer.
Jones previously served as vice president of global pharmaceutical and medicine OTC at Purisys LLC and as vice president business development-global cannabinoids portfolio at Noramco Inc. Prior to that, he was vice president strategic portfolio management at Midas Pharmaceuticals Inc. and previously held leadership roles at Par Sterile Products and Johnson Matthey.
“We are very enthusiastic about Tim joining the Company as CEO and President and, given his outstanding commercial acumen and successful background in cannabinoids and business development, we are confident that he will successfully lead us through the next stage of our development,” Lippa said.
